IDO1 and neoplasm: The incorporation of PTX generates tumor antigens in vivo and induces in situ vaccination, which exploits all relevant antigens in the tumor without the identification of tumor antigens, as an entire array of mutated epitopes is included.[18, 19] The synergistic combination of R848 as TLR 7/8a and EPT as an IDO inhibitor, termed as a supra‐adjuvant, can generate a synergistic effect that involves the up‐regulation of immune‐promoting factors based on tumor antigens and the simultaneous down‐regulation of immunosuppressive factors.